The technology transfer, formalized through a contract signed in March, enables BioLAB to independently conduct chromosome analysis and fluorescence in situ hybridization (FISH) tests. Over 16 weeks, GC Green Cross provided an intensive training program to equip BioLAB’s staff with the necessary skills. The foundation also plans to dispatch specialized personnel to Bahrain to ensure the technology is fully integrated into local operations, moving beyond mere transfer to support on-the-ground implementation.
Historically, BioLAB has outsourced over 150 chromosome analysis cases to GC Green Cross due to growing demand for such diagnostics in Bahrain. By establishing in-house testing capabilities, BioLAB expects to significantly reduce the time and cost associated with transporting samples abroad, while also accelerating patient care delivery.
This initiative represents a strategic pivot for GC Green Cross, which views the project as a launching pad for a new business model focused on technology transfer rather than traditional outsourced testing services. The foundation aims to expand this approach, fostering international partnerships centered on sharing medical expertise.
The move underscores South Korea’s growing influence in the global healthcare sector, as its institutions increasingly share cutting-edge diagnostic technologies with international partners.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
